AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02682303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastic Bandage (Idealplast C®)
Description: Elastic bandage~One anchor strip is applied around the ankle with no tension applied to the tape to avoid restricting blood flow. A supporting stirrup strap is applied from the inside of the ankle, under the heel with no tension up to this point. As the tape is passed up the outside of the ankle tension is applied to the tape with the foot in slight dorsiflexion and secured to the anchor strap (black arrow).~For heel lock, a second strip is applied on the outside of the ankle, taken across the front of the ankle and just above the bony part on the inside of the ankle and back towards the heel (red arrow). Then taken around and under the heel back the way you have just come and around the front of the ankle (orange arrow). The tape then passes above the bony part of the ankle on the outside and diagonally towards the heel, across to the inside of the ankle then around the top to finish
Study NCT02682303 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pretape cramer® (non standarized tape)
Description: Pretape cramer® was used.~The individual is in supine position keeping the foot and ankle in a neutral position.~The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.~This is the only intervention carried out in this group.
Study NCT00937001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy/Ultrasound
Description: obtain muscle biopsies at approximately 14 days of ICU, muscle ultrasound at 3-4 timepoints
Study NCT02356965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single dose of sublingual investigational medication administered when subjects develop moderate to severe pain after third molar extraction.
Study NCT02356965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Ketamine)
Description: Sublingual sugar pill developed to mimic ketamine sublingual dose.
Study NCT00253097 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Intervention
Description: Patients allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate
Study NCT00253097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Patients allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate
Study NCT00623025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon 25000
Description: 6 to 9 capsules Creon 25000 per day
Study NCT00623025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 to 9 capsules placebo per day
Study NCT04505514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside 1000
Description: single dose of 1000 mg iron isomaltoside diluted in 100 ml of 0.9% sodium chloride, infused intravenously over ≥ 20 minutes.~- infusion set will be covered for blinding
Study NCT04505514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 100 ml of 0.9% sodium chloride, infused intravenously over ≥ 20 minutes.~- infusion set will be covered for blinding
Study NCT04505514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberet-Folic-500
Description: once a day dose, to start 5 days after the intervention
Study NCT04505514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iberet-Folic-500
Description: once a day dose, to start 5 days after the intervention
Study NCT01405170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: constituted powder for oral suspension 4 mg/mL single dose at 32 mg
Study NCT01405170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: tablets 32 mg single dose
Study NCT03960437 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Etelcalcetide
Description: Administered intravenously at the end of each dialysis session. Dosing ranges from 5 mg to 15 mg set by the patient's physician.
Study NCT01157442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cell phone sms text messaging
Description: At enrollment a study nurse will send the intervention group a weekly SMS message reminding them to attend antenatal care. Starting at 36 weeks gestational age, an automated bulk SMS management system, will send the intervention group 3 SMS text messages (using non descript slogans) each week by proxy reminding them to take their nevirapine in labor. From time of delivery to 6 weeks postpartum the women will aslo receive 3 SMS messages per week reminding them to attend their 6 week checkup and 6 week infant visit.Upon receiving these messages women in the intervention group can text back if they have any concerns or questions. These women would then receive phone calls from the study nurse triaged according to the women's needs.
Study NCT03872960 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transfer to cardiac arrest centre
Description: Patients in the intervention arm will be taken directly to a the catheter lab of a heart attack centre.
Study NCT05608590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipiodol UltraFluid
Description: The investigational product is an oil-based contrast medium, Lipiodol® (Guerbet). Lipiodol® is a solution of ethyl esters of iodized fatty acids of poppy seed oil equivalent to 480mg I /ml and is a licensed contrast agent in the Netherlands (RVG 02806, see SmPC D2). The maximum amount of Lipiodol® per HSG procedure is 15 ml.
Study NCT05608590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipiodol UltraFluid
Description: The investigational product is an oil-based contrast medium, Lipiodol® (Guerbet). Lipiodol® is a solution of ethyl esters of iodized fatty acids of poppy seed oil equivalent to 480mg I /ml and is a licensed contrast agent in the Netherlands (RVG 02806, see SmPC D2). The maximum amount of Lipiodol® per HSG procedure is 15 ml.
Study NCT03358394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A human-interventional study
Description: The intervention was developed by Ahmed et al. (2017) and was adapted by the investigators for parents of children with T1D. The researcher has received permission form the author to use the script but, not the audio recordings. As a result, we contacted Saab et al. (2016) to get the permission to use the Arabic audio recording of Mindfulness exercises (i.e., introduction to mindfulness practice and mindfulness breathing).~The mindfulness script to be used in the current study is based on MBPT. In this study, we will be using the MBPT programme, but tailored to the needs of parents of children with T1D. One of the main changes in our study is that it will be delivered via the Internet. Participants in the original MBPT programme attended in-person sessions however, Rayan et al. (2016) delivered only the first two sessions in person and the rest via telephone
Study NCT03110952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-PIV
Description: Single-dose vial with pre-filled syringe, subcutaneous injection
Study NCT03110952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-F17
Description: Single-dose vial with pre-filled syringe 0.5 mL administered intramuscularly
Study NCT03110952 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL vial
Study NCT01138150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treximet
Description: One tablet of sumatriptan 85 mg and naproxen sodium 500 mg will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
Study NCT01138150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet of a sugar pill will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
Study NCT01897597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 144807 high dose
Description: oral solution
Study NCT01897597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 144807 intermediate dose
Description: tablet
Study NCT01897597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 144807 intermediate dose
Description: oral solution
Study NCT01897597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 144807 high dose
Description: tablet
Study NCT01620983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training
Study NCT01620983 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arthritis Education
Study NCT02592577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T
Study NCT01620983 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Study NCT04807127 — intervention group
Intervention type: DRUG
Intervention: Immune checkpoint blockade
Description: ICI, administered as standard-of-care treatment
Study NCT02530723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: power training
Description: Resistance training machines with CAM devices will be used for training.
Study NCT04807127 — intervention group
Intervention type: DRUG
Intervention: Targeted therapy
Description: TKI, administered as standard-of-care treatment
Study NCT04807127 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy
Description: RT, administered as standard-of-care treatment
Study NCT03535883 — intervention group
Intervention type: DRUG
Intervention: Novel Oral Anti-Coagulants
Description: Novel Oral Anti-Coagulant (NOAC) medications (i.e. Eliquis, Plavix, Xarelto etc.)
Study NCT00929903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given orally
Study NCT00929903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04915586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg
Description: Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg for total 3 doses within 24 hours
Study NCT04652921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine-guanidinoacetic acid
Description: A dietary supplement provided as powder dissolved in a glass of water
Study NCT04652921 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inulin
Description: A dietary supplement provided as powder dissolved in a glass of water
Study NCT03801096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Based Therapuetic Assessment (NbTa)
Description: The NbTa interventiom will guide participants through an exploration of their human experience through stories and narratives. The interventionist will facilitate a collaborative process by which participants will explore the unique themes and meanings of their personal narrative (Parry \& Doan, 1994) with respect to alcohol and drug use. In addition, participants will also be guided towards considering the re-authorship of personal narratives. The techniques utilized in NbTa aim to dislodge problem saturated narratives and derive more complete personal narratives and meanings (White \& Epston, 1990).
Study NCT03801096 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control Condition (HE)
Description: The Health Education session is a didactic 45-minute session that focusses on three health-related topics: 1) Sleep, 2) Physical Activity, and 3) Nutrition. The goal of the session is to present health-related information to participants through videos and dydadic presentation.
Study NCT01670461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACE
Description: FACE intervention goal is to facilitate conversations about EOL care between adolescents and their legal guardians/surrogates to increase congruence in treatment preferences, to decrease decisional conflict, while supporting plans and actions, psychological adjustment and quality of life. Three 60 to 90-minute sessions in a dyadic format with a trained/certified interviewer. Session 1. The Lyon Family Centered Advance Care Planning Survey©. Session 2. Respecting Choices® Family-Centered Cancer Specific ACP Interview. Session 3. Completion of Five Wishes©.
Study NCT01670461 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of Care (SOC) Control
Description: Standard of Care (SOC) control will be provided with written information that encourages conversation the treatment team. At Children's National the following represent hospital policy:  ... regarding advance directives ... to honor each non-minor patient's wishes ... to encourage and assist patients in determining and expressing their preferences regarding treatment decisions for use in the event they subsequently become unable to make such decisions. Upon admission if they do not have an advance directive, they should be given the Advance Directive Information Booklet and the Advance Directive Checklist. If they already have one, the patient is asked to provide a current copy, and it is placed in the medical record.
Study NCT02589639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Study NCT02589639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02589639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For blinding purposes
Study NCT02589639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For blinding purposes
Study NCT01742325 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: walking
Description: two 20-minute sessions of walking around the nurse's station daily, five days a cycle
Study NCT03270137 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation- IDLPFC
Description: Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC). Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC) compared to six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex \[rDLPFC\]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
Study NCT03270137 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation - Six regions
Description: Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered on six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex \[rDLPFC\]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
Study NCT03765671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor
Description: 120mg oral single dose
Study NCT03409679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Murepavadin
Description: Murepavadin IV every 8 hours + 1 anti-pseudomonal antibiotic (Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin)
Study NCT03409679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two anti-pseudomonal antibiotics
Description: Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin
Study NCT04797715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05
Description: AXS-05 tablets, taken twice daily
Study NCT04797715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, taken twice daily
Study NCT00770315 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ambrosia artemisiifolia allergen extract (Amb a 1-U)
Description: Rapidly dissolving tablet administered sublingually once daily, at a dose of 1.5, 6 or 12 units.
Study NCT00770315 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching Ambrosia artemisiifolia allergen extract rapidly dissolving tablet, administered sublingually once daily
Study NCT05360433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone oral capsule
Description: Reduced initial prescription of oxycodone for postoperative pain management following cesarean section.
Study NCT03409185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcon 1 piece SA60AT lens
Description: Optic Diameter: 6.0 mm, Overall length: 13.0 mm, Material: Ultraviolet-absorbing Acrylate/Methacrylate Copolymer
Study NCT03409185 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMO 1-piece AABOO lens
Description: Optic Diameter: 6.0 mm, Overall length: 13.0 mm, Material: Ultraviolet-blocking hydrophobic acrylic
Study NCT00359970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg
Description: A single 500 mg dose at the start of treatment
Study NCT00359970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin 500 mg
Description: A single 500 mg dose at the start of treatment
Study NCT00359970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin 1000 mg
Description: A single 1000 mg dose at the start of treatment
Study NCT00359970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: A single 4 mg loading dose at the start of treatment and then 2 mg after each loose stool
Study NCT00359970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A single loading dose at the start of treatment and then a dose after each loose stool
Study NCT03114189 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: footbath
Study NCT03114189 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: care of sleep
Study NCT03354351 — intervention group
Intervention type: BEHAVIORAL
Intervention: Stepped-care model
Description: The intervention proposed in this study is a stepped-care model (comprising 3 steps) integrating cognitive-behavioural therapy or trauma-focused therapy and emotion-focused therapy that involves matching individuals to the most appropriate level of care, based on their specific needs . When patients do not show improvement they move to higher, more intensive levels of care.
Study NCT02933385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Risks assessement
Description: Home made questionnaire questioning about the participant's lifestyle habits, risk factors and other.
Study NCT04498390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269
Description: Administered orally.
Study NCT04498390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT03249090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Self-Reporting of Symptoms
Description: At baseline, CRAs will train patients to self-report symptoms and physical functioning weekly for up to a year, with a choice to do so online or via an automated telephone system. Whenever a concerning symptom is reported, an automated email alert notification will be sent to the site CRA. The CRA will forward the alert to the responsible clinical nurse (or other covering clinician) and CC the site's Nurse Champion. Within 72 hours, the CRA will document what action(s), if any, were taken by the nurse in response to the alert (entered by the CRA into a form in the PRO-Core system). A symptom report will be printed/generated by the site CRA whenever the patient has a clinic visit and will be given to the oncologist and nurse caring for the patient.
Study NCT03249090 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Delivery
Description: Patients receive routine cancer care delivery with no additional systematic monitoring of symptoms
Study NCT02717611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196 (acalabrutinib)
Description: ACP-196 100 mg to be administered orally (PO) twice a day BID.
Study NCT04157348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: 30 mg/mL solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC)
Study NCT04157348 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mepolizumab
Description: 3x100 mg vials of powder for solution for injection reconstituted into 3 separate 1 mL syringes for administration on each dosing occasion. Injection volume per syringe is 1 mL. Mepolizumab active solution will be administered subcutaneously (SC)
Study NCT04157348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo to Mepolizumab
Description: Matching placebo: 0.9% sodium chloride, solutions for injection in 1mL syringes (3 syringes will be used on each dosing occasion). Injection volume per syringe is 1mL. Placebo to Mepolizumban will be administered subcutaneously (SC)